27/05/2024 -
Aim to introduce premium instruments to the international market to increase the efficiency of antibody discovery and development worldwide.
27/05/2024 -
Mirus Bio develops & commercializes transfection reagents, which play a critical role in the production of viral vector-based gene therapies.
27/05/2024 -
Will be AstraZeneca’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale.
27/05/2024 -
Will enable ongoing and future work required to potentially generate novel TCRs directed against multiple newly nominated antigen targets.
16/05/2024 -
Worldwide option and license agreement includes AC Immune’s active immunotherapies targeting toxic forms of amyloid beta, including ACI-24.060.